Junshi Biosciences and Coherus Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
April 08, 2022 20:25 ET
|
Junshi Biosciences
SHANGHAI, China, and REDWOOD CITY, Calif., April 09, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for Anti-CD112R Monoclonal Antibody for Treatment of Advanced Solid Tumors
April 03, 2022 07:48 ET
|
Junshi Biosciences
SHANGHAI, China, April 03, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
Junshi Biosciences Announces Full Year 2021 Financial Results and Provides Corporate Updates
March 31, 2022 11:32 ET
|
Junshi Biosciences
-Tackling the COVID-19 pandemic challenge with multi-pronged strategies - Pipeline progressed and expanded substantially SHANGHAI, China, March 31, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi...
Junshi Biosciences Announces First Patient Dosed in China in Phase III Clinical Trial of VV116 in Treatment of Moderate to Severe COVID-19
March 16, 2022 06:30 ET
|
Junshi Biosciences
SHANGHAI, China, March 16, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series
March 15, 2022 09:13 ET
|
Junshi Biosciences
– Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary endpoint of overall survival compared to chemotherapy alone – - Data support the...
Junshi Biosciences and Coherus Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
March 04, 2022 08:00 ET
|
Junshi Biosciences
- Toripalimab plus chemotherapy demonstrates improvement in co-primary endpoints of PFS and OS in patients with advanced ESCC - - PFS and OS benefits were observed across all PD-L1 expression...
Junshi Biosciences and Coherus Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
January 10, 2022 08:58 ET
|
Junshi Biosciences
Junshi Biosciences and Coherus plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor typesCombinations of PD-1 + TIGIT inhibitors have potential to expand...
Junshi Biosciences and DotBio Announce Collaboration to Develop Next-Generation Antibody Therapy with DotBody Module
January 05, 2022 06:00 ET
|
Junshi Biosciences
SHANGHAI, China and SINGAPORE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biociences Co., Ltd (“Junshi Biosciences”, HKEX: 1877, SSE: 688180), a leading innovation-driven biopharmaceutical...
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
December 13, 2021 07:00 ET
|
Junshi Biosciences
SHANGHAI, China and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences,...
Junshi Biosciences Announces NMPA Accepted supplemental New Drug Application for Toripalimab in Combination with Chemotherapy as First-Line Treatment of Advanced NSCLC
December 10, 2021 09:43 ET
|
Junshi Biosciences
SHANGHAI, China, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...